Back to Browse Journals » Cell Health and Cytoskeleton » Volume 2

Bcl-2 family-regulated apoptosis in health and disease

Authors Grant Dewson, Ruth M Kluck

Published Date April 2010 Volume 2010:2 Pages 9—22

DOI http://dx.doi.org/10.2147/CHC.S6228

Published 1 April 2010

Grant Dewson, Ruth M Kluck

Molecular Genetics of Cancer Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

Abstract: Apoptotic cell death is essential for embryonic development, tissue homeostasis, and a well-functioning immune system, with aberrant apoptosis contributing to numerous disease conditions. Inadequate cell death is a major contributing factor to tumorigenesis, while excess cell death contributes to neurodegeneration and autoimmune disease. The major pathway of apoptotic cell death, the mitochondrial pathway, is controlled by the Bcl-2 family of proteins. The members of this family, more than 17 in humans, share significant sequence and structural homology, and fulfil either prosurvival or proapoptotic roles. Specific interactions between these functionally polar proteins, and their relative expression levels, govern the susceptibility of each cell to toxic insults. Here we review the current understanding on how apoptotic cell death is controlled by this important protein family. We also discuss how excessive or insufficient cell death can contribute to disease, and how targeting the Bcl-2 family offers novel therapeutic opportunities.
Keywords: apoptosis, Bcl-2, cancer, cytochrome c, mitochondria

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo [Corrigendum]

Xiang DX, Zheng Y, Duan W, Li XJ, Yin JJ, Shigdar S, O'Connor ML, Marappan M, Zhao XJ, Miao YQ, Xiang B, Zheng CL

International Journal of Nanomedicine 2013, 8:4703-4704

Published Date: 5 December 2013

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:129-130

Published Date: 16 January 2013

Corrigendum

Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1717-1718

Published Date: 26 October 2012

Blood–brain barrier: a real obstacle for therapeutics

Shiekh FA

International Journal of Nanomedicine 2012, 7:4065-4067

Published Date: 27 July 2012

Corrigendum

Hao Z, Zheng L, Kluwe L, Huang W

International Journal of Nanomedicine 2012, 7:2209-2210

Published Date: 3 May 2012

Further data on the association between Helicobacter pylori infection and primary open-angle glaucoma

Zavos C, Kountouras J

Clinical Ophthalmology 2012, 6:243-245

Published Date: 10 February 2012

Erratum

Krikeli M, Ekonomopoulou MT, Tzitzikas I, Goutzioulis A, Mystakidou K, Pistevou-Gompaki K

Cancer Management and Research 2011, 3:319-320

Published Date: 5 December 2011

Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision

Espandar L, Sikder S, Moshirfar M

Clinical Ophthalmology 2011, 5:159-160

Published Date: 6 February 2011

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010